Oregovomab - OncoQuest

Drug Profile

Oregovomab - OncoQuest

Alternative Names: Anti CA125 Mab oregovomab; Anti-CA125-monoclonal-antibody-B43-13-AltaRex; Anti-idiotype-ovarian-cancer-vaccine-AltaRex; Mab B43.13; Monoclonal antibody B43.13; OvaRex; Ovarian-cancer-vaccine-AltaRex

Latest Information Update: 13 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AltaRex
  • Developer National Cancer Centre (Singapore); National Cancer Institute (USA); OncoQuest; University of Nebraska Medical Center
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ovarian cancer; Pancreatic cancer
  • Phase I/II Peritoneal cancer

Most Recent Events

  • 01 Jun 2018 OncoQuest terminates a phase II proof-of-concept trial prematurely in Pancreatic cancer (Combination therapy, Late-stage disease, Second-line therapy or greater), due to the replacement of standard-of-care chemotherapy
  • 01 Jun 2018 Efficacy, adverse events and immunogenicity data from a phase II proof-of-concept trial in Pancreatic cancer released by OncoQuest (9242224; 3327759)
  • 07 Nov 2017 Efficacy data from a phase II trial in Ovarian cancer released by OncoQuest
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top